Targeting B cells in relapsing–remitting multiple sclerosis: from pathophysiology to optimal clinical management
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that is caused by an
autoimmune response against central nervous system (CNS) structures. Traditionally …
autoimmune response against central nervous system (CNS) structures. Traditionally …
B cell-directed therapies in multiple sclerosis
Multiple sclerosis (MS) is a chronic inflammatory neurological disease of the CNS that goes
along with demyelination and neurodegeneration. It is probably caused by an autoimmune …
along with demyelination and neurodegeneration. It is probably caused by an autoimmune …
Therapeutic strategies targeting B-cells in multiple sclerosis
R Milo - Autoimmunity reviews, 2016 - Elsevier
Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease of the central
nervous system (CNS) that traditionally has been considered to be mediated primarily by T …
nervous system (CNS) that traditionally has been considered to be mediated primarily by T …
B cells in multiple sclerosis—from targeted depletion to immune reconstitution therapies
MT Cencioni, M Mattoscio, R Magliozzi… - Nature Reviews …, 2021 - nature.com
Increasing evidence indicates the involvement of B cells in the pathogenesis of multiple
sclerosis (MS), but their precise roles are unclear. In this Review, we provide an overview of …
sclerosis (MS), but their precise roles are unclear. In this Review, we provide an overview of …
Anti-CD20 B cell treatment for relapsing multiple sclerosis
CA Roach, AH Cross - Frontiers in neurology, 2021 - frontiersin.org
Several clinical trials have demonstrated the efficacy of lytic therapies targeting B cells in the
treatment of relapsing multiple sclerosis (MS). More modest efficacy has been noted in the …
treatment of relapsing multiple sclerosis (MS). More modest efficacy has been noted in the …
[HTML][HTML] Therapies for multiple sclerosis targeting B cells
R Milo - Croatian medical journal, 2019 - ncbi.nlm.nih.gov
Increasing evidence suggests that B cells contribute both to the regulation of normal
autoimmunity and to the pathogenesis of immune mediated diseases, including multiple …
autoimmunity and to the pathogenesis of immune mediated diseases, including multiple …
B-cell therapies in multiple sclerosis
JJ Sabatino, SS Zamvil… - Cold Spring …, 2019 - perspectivesinmedicine.cshlp.org
B cells play a vital function in multiple sclerosis (MS) pathogenesis through an array of
effector functions. All currently approved MS disease–modifying therapies alter the …
effector functions. All currently approved MS disease–modifying therapies alter the …
B‐cell Therapy for Multiple Sclerosis: Entering an era
AL Greenfield, SL Hauser - Annals of neurology, 2018 - Wiley Online Library
Monoclonal antibodies that target CD20 expressing B cells represent an important new
treatment option for patients with multiple sclerosis (MS). B‐cell‐depleting therapy is highly …
treatment option for patients with multiple sclerosis (MS). B‐cell‐depleting therapy is highly …
B cell depletion in the treatment of multiple sclerosis
KM Myhr, Ø Torkildsen, A Lossius, L Bø… - Expert opinion on …, 2019 - Taylor & Francis
Introduction: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous
system. The latest development of B-cell depletion by anti-CD20 monoclonal antibodies has …
system. The latest development of B-cell depletion by anti-CD20 monoclonal antibodies has …
Role of B cells in multiple sclerosis and related disorders
G Comi, A Bar‐Or, H Lassmann, A Uccelli… - Annals of …, 2021 - Wiley Online Library
The success of clinical trials of selective B‐cell depletion in patients with relapsing multiple
sclerosis (MS) and primary progressive MS has led to a conceptual shift in the …
sclerosis (MS) and primary progressive MS has led to a conceptual shift in the …